Mulling Over Mutations: NRAS-Mutated and BRAF-Mutated Melanomas Are Biologically Distinct

BRAF mutations were associated with thinner lesions and superficial, spreading melanomas; NRAS mutations with nodular melanomas.

The influence of BRAF or NRAS mutations in melanoma has become a crucial determinant in treatment decisions in the era of targeted therapies. Are tumors associated with these mutations clinicopathologically or biologically distinct? A recent meta-analysis of studies examining this issue produced some interesting conclusions.

In 36 studies of BRAF mutations and melanoma, BRAF mutations were detected in 1028 (41%) of 2521 patients. BRAF mutations were reported in 492 (49%) of 999 superficial spreading melanomas (SSMs); 116 (41%) of 282 nodular melanomas (NMs); 42 (22%) of 195 lentigo maligna melanomas (LMs); and 25 (20%) of 123 acral lentiginous melanomas (ALMs). BRAF mutations were positively associated with SSM (P<0,001) and negatively assoc…

Reviewing Author

Hensin Tsao, MD, PhD

Disclosures

Consultant / advisory board Lubax; WorldCare Clinical

EquityLubax

Grant / Research support NIH; Department of Defense; American Skin Association; Piramal

Editorial boardsBritish Journal of Dermatology; Journal of the American Academy of Dermatology; Journal of Investigative Dermatology

Leadership positions in professional societies American Academy of Dermatology (Chair, Skin Cancer and Melanoma Committee); American Board of Dermatology (Director)